In our study, we conducted a network meta-analysis of randomized controlled trials to evaluate the efficacy and safety of various EGFR-TKI and EGFR-TKI combination therapies for advanced NSCLC with EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.